Notice of filing of new patent application for VAL001
Respiratorius announces that a patent application for the completed formulation of VAL001 has been filed. The patent application protects the formulation of valproate, which in a PK study has shown expected results.The patent application protects a new oral formulation of sodium valproate for the pretreatment of cancer, as well as any other use of the formulation. The application is valid for at least 20 years from the date of priority, during which time it confers exclusive rights on the market. The tailored release profile of VAL001, which combines immediate-release and delayed-